Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 24, 2026
Reporting Period: Specific event date of June 24, 2026.
Business Context: The filing discloses amendments to executive employment and severance agreements for the CEO, CFO, and Chief Development Officer, approved by the Board of Directors following a review by the Compensation Committee.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes Versus Prior Period
The filing details specific changes to executive compensation structures effective June 24, 2026:
- CEO (Dr. Angelos Stergiou): Amendment to the employment agreement to provide that certain change in control severance benefits will be paid in a lump sum. All other terms remain unchanged.
- CFO (John Burns) and CDO (Dr. Dragan Cicic): Amended and restated severance and change of control letter agreements replacing prior agreements.
Guidance, Outlook, and Management Commentary
Executive Severance Terms (Burns and Cicic Agreements):
- Non-Change of Control Termination: If terminated without Cause or resigns for Good Reason outside the Change of Control Period, executives receive:
- 9 months of base salary.
- Pro rata target bonus for the year of termination.
- COBRA premium reimbursement for up to 9 months.
- Change of Control Termination: If terminated without Cause or resigns for Good Reason within one month prior to or one year following a Change of Control, executives receive:
- Lump sum payment equal to 15 months of base salary.
- Lump sum payment equal to the full target bonus for the year of termination.
- COBRA premium reimbursement for up to 18 months.
- Immediate full vesting of all unvested equity awards.
Conditions: Receipt of severance is conditioned upon the execution of a separation and general release agreement.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies beyond the standard conditions attached to the severance agreements.
Important Facts for Investor Verification
- Verify the specific dollar amounts of base salaries and target bonuses for Dr. Stergiou, Mr. Burns, and Dr. Cicic to calculate potential severance liabilities.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for complete legal definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the total value of unvested equity awards held by the CFO and CDO as of the termination date to assess the impact of immediate vesting provisions.
- Check subsequent filings for any actual triggering events related to these severance agreements.